Statin Therapy Guidelines

Introduction to Statin Therapy

The American College of Cardiology recommends that patients starting statin therapy be warned to immediately report any unexplained muscle pain, tenderness, weakness, or cramping, as these symptoms may indicate potentially serious muscle injury that requires prompt evaluation and possible discontinuation of the medication 1, 2

Muscle symptoms (pain, soreness, tenderness, weakness, or cramping) are the most important warning to communicate, as they may indicate myopathy or, rarely, life-threatening rhabdomyolysis 1, 2, 3
Patients should report muscle symptoms immediately, especially if accompanied by dark urine, fever, or unusual fatigue 2, 3
Severe muscle pain or weakness that interferes with daily activities should be reported immediately 2, 3
Dark or cola-colored urine (suggesting myoglobinuria from muscle breakdown) should be reported immediately 4

The American College of Cardiology warns that patients taking statins should inform all healthcare providers about their statin use, as dangerous interactions can occur with certain medications, including gemfibrozil, cyclosporine, macrolide antibiotics, antifungal agents, niacin, and cytochrome P-450 inhibitors 1, 5, 6
Patients should carry a medication list and show it to any prescriber, including urgent care providers and specialists 5

Moderate strenuous exercise or work during the first weeks of therapy, as vigorous activity can increase muscle symptom risk 3
If muscle soreness develops, reduce activity intensity and report symptoms to determine if they are exercise-related or statin-related 3

The American College of Cardiology recommends that surgeons be informed about statin use, as statins should likely be withheld during hospitalization for major surgery due to increased myopathy risk 1, 2, 5

Active or chronic liver disease is an absolute contraindication to statin therapy 1, 2

The American College of Cardiology identifies advanced age (especially >80 years), kidney disease, multiple medications, and hypothyroidism as risk-enhancing patient characteristics that require special consideration 1, 2, 5, 7

Patients should expect baseline evaluation before starting therapy, follow-up at 6-12 weeks, and then at regular intervals 4, 7
Blood tests (CK levels) will be obtained only if muscle symptoms develop, not routinely in asymptomatic patients 2, 6